First Time Loading...

Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.98 EUR
Updated: May 6, 2024

Heidelberg Pharma AG
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Heidelberg Pharma AG
Operating Income Peer Comparison

Comparables:
BNTX
MOR
IMTX
BIO
FYB

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Heidelberg Pharma AG
XETRA:HPHA
Operating Income
-€21.3m
CAGR 3-Years
-5%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Operating Income
€908m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Operating Income
-€232.9m
CAGR 3-Years
N/A
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Operating Income
-€101.7m
CAGR 3-Years
-13%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Operating Income
€120.3m
CAGR 3-Years
N/A
CAGR 5-Years
57%
CAGR 10-Years
8%
Formycon AG
XETRA:FYB
Operating Income
-€17.7m
CAGR 3-Years
-100%
CAGR 5-Years
-64%
CAGR 10-Years
N/A

See Also

What is Heidelberg Pharma AG's Operating Income?
Operating Income
-21.3m EUR

Based on the financial report for Nov 30, 2023, Heidelberg Pharma AG's Operating Income amounts to -21.3m EUR.

What is Heidelberg Pharma AG's Operating Income growth rate?
Operating Income CAGR 5Y
-12%

Over the last year, the Operating Income growth was -17%. The average annual Operating Income growth rates for Heidelberg Pharma AG have been -5% over the past three years , -12% over the past five years .